CHEST pulmonary最新文献

筛选

英文中文

CHEST pulmonary Pub Date : 2023-06-01 DOI: 10.1016/j.chpulm.2023.100004

Michael Glenn O’Connor MD , Ricardo Mosquera MD , Hilda Metjian MD , Meghan Marmor MD , Kenneth N. Olivier MD, MPH , Adam J. Shapiro MD

{"title":"Primary Ciliary Dyskinesia","authors":"Michael Glenn O’Connor MD , Ricardo Mosquera MD , Hilda Metjian MD , Meghan Marmor MD , Kenneth N. Olivier MD, MPH , Adam J. Shapiro MD","doi":"10.1016/j.chpulm.2023.100004","DOIUrl":"https://doi.org/10.1016/j.chpulm.2023.100004","url":null,"abstract":"<div><p>Primary ciliary dyskinesia (PCD) is a rare but underdiagnosed disorder that affects motile cilia function throughout the body. With increasing prevalence through ongoing genetic discovery, PCD underlies the disease process in a significant number of patients with chronic suppurative lung disease and bronchiectasis when properly investigated using current diagnostic standards. Classic PCD symptoms include chronic rhinosinusitis and otitis, organ laterality defects, infertility, year-round productive cough, and recurrent pneumonias with bronchiectasis. Clinical symptoms of PCD manifest very early in life (often at birth), although diagnosis frequently is delayed because of poor phenotypic recognition and limited access to specialized diagnostic testing. In the past decade, PCD research networks have established specific PCD phenotypes to increase clinical recognition, and the availability of PCD genetic panels in various commercial laboratories has expanded access to an accurate PCD diagnosis greatly. Clinical practice guidelines also were created to guide diagnosis and management of this rare but increasingly recognized suppurative respiratory disease. PCD is more common than previously thought and can be recognized through specific clinical phenotypes in both children and adults. Diagnostic PCD testing outside of highly specialized centers can be difficult, but increased availability of nasal nitric oxide measurement and commercial genetic panels now allows for noninvasive screening and definitive diagnosis regardless of center expertise. Identification of patients with accurately diagnosed PCD is needed worldwide to populate future clinical trials and to develop disease-specific therapies for PCD.</p></div>","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":"1 1","pages":"Article 100004"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49703082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Announcing the Launch of CHEST Pulmonary and the CHEST Portfolio of Journals 宣布推出CHEST Pulmonary和CHEST期刊组合

CHEST pulmonary Pub Date : 2023-06-01 DOI: 10.1016/j.chpulm.2023.100001

Matthew C. Miles MD, MEd, FCCP

引用次数: 0

Mobile Health for Asthma 哮喘流动医疗

CHEST pulmonary Pub Date : 2023-06-01 DOI: 10.1016/j.chpulm.2023.100002

Andrew Kouri MD, PhD , Samir Gupta MD

{"title":"Mobile Health for Asthma","authors":"Andrew Kouri MD, PhD , Samir Gupta MD","doi":"10.1016/j.chpulm.2023.100002","DOIUrl":"https://doi.org/10.1016/j.chpulm.2023.100002","url":null,"abstract":"<div><p>Asthma is a highly prevalent disease associated with significant individual and health system-level burdens. Mobile health (mHealth) apps and connected mobile digital devices, all of which are in the category of mHealth, may have the potential to address many of the important care gaps in asthma. In this narrative review, we document the current state of asthma mHealth for adults, discuss the main challenges to widespread asthma mHealth adoption, and explore future possibilities for asthma mHealth. The number of asthma mHealth options is growing, classified into four discrete categories based on technology type: standalone apps, digital inhalers, digital spirometers, and other mHealth devices used in asthma care. Evidence for asthma mHealth effectiveness is emerging, but systematic assessment is challenging because of technological heterogeneity. To attain more general clinical viability, challenges include advancing the evidence for mHealth effectiveness; promoting accessibility and inclusivity; sustaining patient engagement and successful integration into clinical workflows; ensuring mHealth safety; and considering future regulatory, economic, and pedagogical needs. If these challenges are met, asthma mHealth may help to deliver personalized digital asthma care when combined with novel artificial intelligence approaches, to improve the validity of future asthma research, and to enhance the provision of virtual asthma care. As mobile technology becomes a greater part of our lives and investment and interest in mHealth continues to grow, providers who care for patients with asthma must prepare for this mHealth digital revolution and lobby for safe, effective, and equitable mHealth solutions.</p></div>","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":"1 1","pages":"Article 100002"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49756941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

首页上一页